Low dose estrogen interrupted hormone replacement therapy

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07078394

ABSTRACT:
A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17β-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 μg per day of norgestimate.

REFERENCES:
patent: 4957119 (1990-09-01), De Nijs
patent: 5088505 (1992-02-01), De Nijs
patent: 5108995 (1992-04-01), Casper
patent: 5256421 (1993-10-01), Casper
patent: 5276022 (1994-01-01), Casper
patent: 5382573 (1995-01-01), Casper
patent: 5422119 (1995-06-01), Casper
patent: 5585370 (1996-12-01), Casper
patent: 5633242 (1997-05-01), Oettel et al.
patent: 6133251 (2000-10-01), Dittgen et al.
patent: 44 29 374 (1996-02-01), None
patent: 0 275 716 (1988-07-01), None
patent: 0 309 263 (1989-03-01), None
patent: 0 770 388 (1997-05-01), None
patent: WO 97/11680 (1997-04-01), None
patent: WO 98/37897 (1998-09-01), None
Lobo, et al., “A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles,” Am. J. of Obstet. & Gynecol., vol. 182, No. 1, Part 1, Jan. 2000, pp. 41-49 (XP-000900454).
Sulak, et al., “Efficacy and Safety of a Constant-Estrogen, Pulsed-Progestin Regimen in Hormone Replacement Therapy,” Int'l. Journal of Fertility and Women's Medicine, Nov.-Dec. 1999, pp. 286-196 (XP-000934379).
Vanin, et al., “Lumbar vertebral density and mechanical properties in aged ovariectomized rats treated with estrogen and norethindrone or norgestimate,” Am. J. Obstet. & Gynecol., vol. 173, No. 5, Nov. 1995, pp. 1491-1498 (XP-000934383).
Christin-Matrie, et al., “Perceptives de la contraception,” La Revue du Practicien, 1995, pp. 2449-2453 (English abstract on p. 2453 (last page)).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Low dose estrogen interrupted hormone replacement therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low dose estrogen interrupted hormone replacement therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose estrogen interrupted hormone replacement therapy will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3526315

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.